Discovery of potential sclerostin inhibitors from plants with loop2 region of sclerostin inhibition by interacting with residues outside Pro-Asn-Ala-Ile-Gly motif

References

• Balemans, W., Ebeling, M., Patel, N., Van Hul, E., Olson, P., Dioszegi, M., … Willems, P. (2001). Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Human Molecular Genetics, 10(5), 537–544. doi: 10.1093/hmg/10.5.537
   PubMed Web of Science ®Google Scholar
• Bayly, C. I., Cieplak, P., Cornell, W., & Kollman, P. A. (1993). A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. The Journal of Physical Chemistry, 97(40), 10269–10280. doi: 10.1021/j100142a004
   Web of Science ®Google Scholar
• Beck, D. A., & Daggett, V. (2004). Methods for molecular dynamics simulations of protein folding/unfolding in solution. Methods, 34(1), 112–120. doi: 10.1016/j.ymeth.2004.03.008
   PubMed Web of Science ®Google Scholar
• Boschert, V., van Dinther, M., Weidauer, S., van Pee, K., Muth, E.-M., ten Dijke, P., & Mueller, T. D. (2013). Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition. PLoS One, 8(11), e81710. doi: 10.1371/journal.pone.0081710
   PubMed Web of Science ®Google Scholar
• Bourhis, E., Wang, W., Tam, C., Hwang, J., Zhang, Y., Spittler, D., … Cochran, A. G. (2011). Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Structure, 19(10), 1433–1442. doi: 10.1016/j.str.2011.07.005
   PubMed Web of Science ®Google Scholar
• Burley, S., & Petsko, G. A. (1985). Aromatic-aromatic iInteraction: A mechanism of protein structure stabilization. Science, 229(4708), 23–28. doi: 10.1126/science.3892686
   PubMed Web of Science ®Google Scholar
• Chu, W.-T., Zheng, Q.-C., Wu, Y.-J., Zhang, J.-L., Liang, C.-Y., Chen, L., … Zhang, H.-X. (2013). Molecular dynamics (MD) simulations and binding free energy calculation studies between inhibitors and type II dehydroquinase (DHQ2). Molecular Simulation, 39(2), 137–144. doi: 10.1080/08927022.2012.708416
   Web of Science ®Google Scholar
• Clarke, B. L. (2009). New and emerging treatments for osteoporosis. Clinical Endocrinology, 71(3), 309–321. doi: 10.1111/j.1365-2265.2009.03541.x
   PubMed Web of Science ®Google Scholar
• Clarke, B. L. (2014). Anti-sclerostin antibodies: Utility in treatment of osteoporosis. Maturitas, 78(3), 199–204. doi: 10.1016/j.maturitas.2014.04.016
   PubMed Web of Science ®Google Scholar
• Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., … Grauer, A. (2016). Romosozumab treatment in postmenopausal women with osteoporosis. New England Journal of Medicine, 375(16), 1532–1543. doi: 10.1056/NEJMoa1607948
   PubMed Web of Science ®Google Scholar
• Costa, A. G., Bilezikian, J. P., & Lewiecki, E. M. (2014). Update on romosozumab: A humanized monoclonal antibody to sclerostin. Expert Opinion on Biological Therapy, 14(5), 697–707. doi: 10.1517/14712598.2014.895808
   PubMed Web of Science ®Google Scholar
• Crockett, J. C., Rogers, M. J., Coxon, F. P., Hocking, L. J., & Helfrich, M. H. (2011). Bone remodelling at a glance. Journal of Cell Science, 124(Pt 7), 991–998. doi: 10.1242/jcs.063032
   PubMed Web of Science ®Google Scholar
• Cruz, J. N., Costa, J. F., Khayat, A. S., Kuca, K., Barros, C. A., & Neto, A. (2018). Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis polyketide synthase 13. Journal of Biomolecular Structure and Dynamics, 37(6), 1616–1627.
   PubMed Web of Science ®Google Scholar
• De Vries, S. J., Van Dijk, M., & Bonvin, A. M. (2010). The HADDOCK web server for data-driven biomolecular docking. Nature Protocols, 5(5), 883–897. doi: 10.1038/nprot.2010.32
   PubMed Web of Science ®Google Scholar
• Dominguez, C., Boelens, R., & Bonvin, A. M. (2003). HADDOCK: A protein–protein docking approach based on biochemical or biophysical information. Journal of the American Chemical Society, 125(7), 1731–1737. doi: 10.1021/ja026939x
   PubMed Web of Science ®Google Scholar
• Garg, S. K. (2015). Diagnosis & treatment of osteoporosis: Are we doing enough? Journal of Bone Reports & Recommendations, 1, 1–4.
   Google Scholar
• Ge, Y., Wu, J., Xiao, J., & Yu, J. (2011). Exploration of the binding mode of α/β-type small acid soluble proteins (SASPs) with DNA. Journal of Molecular Modeling, 17(12), 3183–3193. doi: 10.1007/s00894-011-1007-6
   PubMed Web of Science ®Google Scholar
• Guo, A. J. Y., Choi, R. C. Y., Cheung, A. W. H., Chen, V. P., Xu, S. L., Dong, T. T. X., … Tsim, K. W. K. (2011). Baicalin, a flavone, induces the differentiation of cultured osteoblasts: An action via the Wnt/β-catenin signaling. Journal of Biological Chemistry, 286(32), 27882–27893. doi: 10.1074/jbc.M111.236281
   PubMed Web of Science ®Google Scholar
• Holdsworth, G., Slocombe, P., Doyle, C., Sweeney, B., Veverka, V., Le Riche, K., … Robinson, M. K. (2012). Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. Journal of Biological Chemistry, 287(32), 26464–26477. doi: 10.1074/jbc.M112.350108
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. (2011). Osteoporosis fact sheet. Retrieved from http://www.iofbonehealth.org/.
   Google Scholar
• Jia, M., Nie, Y., Cao, D. P., Xue, Y. Y., Wang, J. S., Zhao, L., … Qin, L. P. (2012). Potential antiosteoporotic agents from plants: A comprehensive review. Evidence-Based Complementary and Alternative Medicine, 2012, 1–28. doi: 10.1155/2012/364604
   Google Scholar
• Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W., & Klein, M. L. (1983). Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics, 79(2), 926–935. doi: 10.1063/1.445869
   Web of Science ®Google Scholar
• Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012). Sclerostin and dickkopf-1 as therapeutic targets in bone diseases. Endocrine Reviews, 33(5), 747–783. doi: 10.1210/er.2011-1060
   PubMed Web of Science ®Google Scholar
• Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., … Cheatham, T. E. (2000). Calculating structures and free Eeergies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33(12), 889–897. doi: 10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Lewiecki, E. M., Blicharski, T., Goemaere, S., Lippuner, K., Meisner, P. D., Miller, P. D., … Horlait, S. (2018). A phase 3 randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. The Journal of Clinical Endocrinology & Metabolism, 103(9), 3183–3193. doi: 10.1210/jc.2017-02163
   PubMed Web of Science ®Google Scholar
• Li, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., … Paszty, C. (2008). Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 23(6), 860–869. doi: 10.1359/jbmr.080216
   PubMed Web of Science ®Google Scholar
• Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., … Paszty, C. (2009). Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 24(4), 578–588. doi: 10.1359/jbmr.081206
   PubMed Web of Science ®Google Scholar
• Li, X., Warmington, K. S., Niu, Q.-T., Asuncion, F. J., Barrero, M., Grisanti, M., … Ke, H. Z. (2010). Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 25(12), 2647–2656. doi: 10.1002/jbmr.182
   PubMed Web of Science ®Google Scholar
• Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., … Wu, D. (2005). Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry, 280(20), 19883–19887. doi: 10.1074/jbc.M413274200
   PubMed Web of Science ®Google Scholar
• Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. doi: 10.1021/acs.jctc.5b00255
   PubMed Web of Science ®Google Scholar
• Makras, P., Delaroudis, S., & Anastasilakis, A. D. (2015). Novel therapies for osteoporosis. Metabolism: Clinical and Experimental, 64(10), 1199–1214. doi: 10.1016/j.metabol.2015.07.011
   PubMed Web of Science ®Google Scholar
• Miller, B. R., III, McGee, T. D., Jr, Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA.py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321. doi: 10.1021/ct300418h
   PubMed Web of Science ®Google Scholar
• Nadvorny, D., Soares-Sobrinho, J. L., de La Roca Soares, M. F., Ribeiro, A. J., Veiga, F., & Seabra, G. M. (2018). Molecular dynamics simulations reveal the influence of dextran sulfate in nanoparticle formation with calcium alginate to encapsulate insulin. Journal of Biomolecular Structure and Dynamics, 36(5), 1255–1260. doi: 10.1080/07391102.2017.1318305
   PubMed Web of Science ®Google Scholar
• Onufriev, A., Bashford, D., & Case, D. A. (2004). Exploring protein native states and large‐scale conformational changes with a modified generalized born model. Proteins: Structure, Function, and Bioinformatics, 55(2), 383–394. doi: 10.1002/prot.20033
   PubMed Web of Science ®Google Scholar
• Pastor, R. W., Brooks, B. R., & Szabo, A. (1988). An analysis of the accuracy of langevin and molecular dynamics algorithms. Molecular Physics, 65(6), 1409–1419. doi: 10.1080/00268978800101881
   Web of Science ®Google Scholar
• Pradiba, D., Aarthy, M., Shunmugapriya, V., Singh, S. K., & Vasanthi, M. (2018). Structural insights into the binding mode of flavonols with the active site of matrix metalloproteinase-9 through molecular docking and molecular dynamic simulations studies. Journal of Biomolecular Structure and Dynamics, 36(14), 3718–3739. doi: 10.1080/07391102.2017.1397058
   PubMed Web of Science ®Google Scholar
• Roe, D. R., & Cheatham, T. E. III, (2013). PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. Journal of Chemical Theory and Computation, 9(7), 3084–3095. doi: 10.1021/ct400341p
   PubMed Web of Science ®Google Scholar
• Ryckaert, J. P., Ciccotti, G., & Berendsen, H. J. (1977). Numerical integration of the Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Journal of Computational Physics, 23(3), 327–341. doi: 10.1016/0021-9991(77)90098-5
   Web of Science ®Google Scholar
• Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., … Grauer, A. (2017). Romosozumab or alendronate for fracture prevention in women with osteoporosis. New England Journal of Medicine, 377(15), 1417–1427. doi: 10.1056/NEJMoa1708322
   PubMed Web of Science ®Google Scholar
• Silverman, S. L. (2010). Sclerostin. Journal of Osteoporosis, 2010, 1–3. doi: 10.4061/2010/941419
   Google Scholar
• Suen, P. K., & Qin, L. (2016). Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review. Journal of Orthopaedic Translation, 4, 1–13. doi: 10.1016/j.jot.2015.08.004
   PubMed Web of Science ®Google Scholar
• Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., … Carr, M. D. (2009). Characterization of the structural features and interactions of sclerostin molecular insight into a key regulator of Wnt-mediated bone formation. Journal of Biological Chemistry, 284(16), 10890–10900. doi: 10.1074/jbc.M807994200
   PubMed Web of Science ®Google Scholar
• Wang, J., Hou, T., & Xu, X. (2006). Recent advances in free energy calculations with a combination of molecular mechanics and continuum models. Current Computer Aided-Drug Design, 2(3), 287–306. doi: 10.2174/157340906778226454
   Web of Science ®Google Scholar
• Weiser, J., Shenkin, P. S., & Still, W. C. (1999). Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO). Journal of Computational Chemistry, 20(2), 217–230. doi: 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A
   Web of Science ®Google Scholar
• Williams, L. D. (2018). Molecular interactions (noncovalent interactions) in biochemical systems. Retrieved from https://ww2.chemistry.gatech.edu
   Google Scholar
• Yavropoulou, M. P., Xygonakis, C., Lolou, M., Karadimou, F., & Yovos, J. G. (2014). The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis. Hormones, 13(4), 476–487.
   Google Scholar
• Zacharias, N., & Dougherty, D. A. (2002). Cation–π interactions in ligand recognition and catalysis. Trends in Pharmacological Sciences, 23(6), 281–287. doi: 10.1016/S0165-6147(02)02027-8
   PubMed Web of Science ®Google Scholar